Industry
Felix Faupel, Chief Commercial Officer at Bacthera, discussed how the combination of the new Lonza Capsugel® Enprotect™ capsule and Bacthera services will accelerate time-to-human and time-to-market.
The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy with proven effectiveness, including identifying cancer in its earliest stages
Gynecologist Franco Vicariotto and Virginia Franco, CEO and Co-Founder Yoni Solutions, discuss how personalized analysis and personalized therapy are within the reach of today's woman.
Funding round led by Shanghai Healthcare Capital. The financing round will enable Biomica to forge ahead, developing its pipeline of microbiome-based therapeutics.
Biopharma companies are currently developing Live Biotherapeutic Products. We discussed this topic with Morten Isaksen (BIO-ME).
Strategic investment in dynamic research field of skin microbiome to drive future of skin care.
Emily Hollister discussed how Diversigen demonstrates the rapidity of microbial gene expression changes potentially impacting host-microbiome interactions.
With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases.
The new group will have annual revenues of approximately 3.5 billion euros ($3.7 billion), the companies said.
FB-001 is a rationally designed consortium of 148 defined bacterial strains with unprecedented diversity, representing a complete microbiome replacement
